Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JERALD H SIMMONS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1417045329
CMS profile
109538
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,551.84

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,481.85 50
Education $69.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JERALD H SIMMONS

NPI 1417045329 · CMS profile ID 109538

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417045329?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JERALD H SIMMONS, NPI 1417045329, CMS profile ID 109538. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417045329?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JERALD H SIMMONS, NPI 1417045329, CMS profile ID 109538. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417045329?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JERALD H SIMMONS, NPI 1417045329, CMS profile ID 109538, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1417045329?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $1,551.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Inspire Medical Systems, Inc. $6.0901/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251509480 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47,639.52 87
PY2020 $40,019.19 69
PY2021 $17,504.15 40
PY2022 $14,338.96 32
PY2023 $35,886.00 77
PY2024 $8,413.45 52
PY2025 $1,551.84 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $238,817.55 201
PY2024 Principal investigator $343,089.53 252
PY2023 Recipient $1,283.16 4
PY2023 Principal investigator $102,793.28 22
PY2022 Principal investigator $17,872.03 9
PY2021 Principal investigator $118,621.20 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

201 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617411
Principal investigator 1 Alkermes, Inc. $1,500.00 12/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614799
Principal investigator 1 Alkermes, Inc. $2,000.00 12/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621208
Principal investigator 1 Alkermes, Inc. $279.00 12/10/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615391
Principal investigator 1 Alkermes, Inc. $2,040.00 12/10/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625882
Principal investigator 1 Alkermes, Inc. $1.40 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617729
Principal investigator 1 Alkermes, Inc. $50.00 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619409
Principal investigator 1 Alkermes, Inc. $0.35 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619893
Principal investigator 1 Alkermes, Inc. $0.70 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624510
Principal investigator 1 Alkermes, Inc. $164.16 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625387
Principal investigator 1 Alkermes, Inc. $100.30 12/04/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626038
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738423
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.70 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738425
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.20 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738427
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.08 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738429
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738431
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738433
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.84 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738435
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $59.64 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738437
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.35 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738439
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $21.07 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738441
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.78 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738443
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738445
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738447
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738449
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738451
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738453
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $72.24 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738455
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738457
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.14 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738459
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.06 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738461
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738463
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738465
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.35 11/24/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738467
Principal investigator 1 Alkermes, Inc. $1,848.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614797
Principal investigator 1 Alkermes, Inc. $644.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616041
Principal investigator 1 Alkermes, Inc. $739.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619179
Principal investigator 1 Alkermes, Inc. $276.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619655
Principal investigator 1 Alkermes, Inc. $276.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621843
Principal investigator 1 Alkermes, Inc. $644.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625161
Principal investigator 1 Alkermes, Inc. $3,402.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625391
Principal investigator 1 Alkermes, Inc. $2,010.00 11/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626898
Principal investigator 1 Alkermes, Inc. $1,189.00 11/10/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619895
Principal investigator 1 Alkermes, Inc. $279.00 11/10/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621610
Principal investigator 1 Alkermes, Inc. $25.70 11/05/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621204
Principal investigator 1 Alkermes, Inc. $12.85 11/05/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622053
Principal investigator 1 Alkermes, Inc. $51.40 11/05/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623816
Principal investigator 1 Alkermes, Inc. $6,848.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614565
Principal investigator 1 Alkermes, Inc. $1,848.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614795
Principal investigator 1 Alkermes, Inc. $58.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616681
Principal investigator 1 Alkermes, Inc. $138.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618463
Principal investigator 1 Alkermes, Inc. $276.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620341
Principal investigator 1 Alkermes, Inc. $68.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622263
Principal investigator 1 Alkermes, Inc. $2,134.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622683
Principal investigator 1 Alkermes, Inc. $86.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625640
Principal investigator 1 Alkermes, Inc. $4,788.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626042
Principal investigator 1 Alkermes, Inc. $43.00 10/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626440
Principal investigator 1 Alkermes, Inc. $34.35 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613043
Principal investigator 1 Alkermes, Inc. $36.40 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614559
Principal investigator 1 Alkermes, Inc. $77.10 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614793
Principal investigator 1 Alkermes, Inc. $1.74 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615023
Principal investigator 1 Alkermes, Inc. $2.10 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617343
Principal investigator 1 Alkermes, Inc. $8.56 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621396
Principal investigator 1 Alkermes, Inc. $12.84 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622922
Principal investigator 1 Alkermes, Inc. $74.24 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623158
Principal investigator 1 Alkermes, Inc. $0.70 10/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626252
Principal investigator 1 Alkermes, Inc. $1,936.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614054
Principal investigator 1 Alkermes, Inc. $3,402.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614723
Principal investigator 1 Alkermes, Inc. $2,029.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617865
Principal investigator 1 Alkermes, Inc. $4,669.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617867
Principal investigator 1 Alkermes, Inc. $6,702.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618125
Principal investigator 1 Alkermes, Inc. $3,944.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619071
Principal investigator 1 Alkermes, Inc. $2,134.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624638
Principal investigator 1 Alkermes, Inc. $712.00 09/08/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625792
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613397
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622811
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623066
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625790
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $26,028.34 08/21/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738421
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615451
Principal investigator 1 Alkermes, Inc. $1,879.00 07/09/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614483
Principal investigator 1 Alkermes, Inc. $8,000.00 07/09/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619305
Principal investigator 1 Alkermes, Inc. $51.40 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613788
Principal investigator 1 Alkermes, Inc. $16.08 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620700
Principal investigator 1 Alkermes, Inc. $2.80 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621736
Principal investigator 1 Alkermes, Inc. $72.80 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623064
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612997
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613137
Principal investigator 1 Alkermes, Inc. $38.55 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613599
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613800
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614088
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614290
Principal investigator 1 Alkermes, Inc. $8.55 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614643
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616127
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616623
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616643
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619337
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619517
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619597
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620712
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621070
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621502
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621760
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621776
Principal investigator 1 Alkermes, Inc. $6.42 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622221
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623264
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623584
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623760
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624444
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625491
Principal investigator 1 Alkermes, Inc. $119.36 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613810
Principal investigator 1 Alkermes, Inc. $259.54 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617045
Principal investigator 1 Alkermes, Inc. $82.08 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617879
Principal investigator 1 Alkermes, Inc. $77.64 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618133
Principal investigator 1 Alkermes, Inc. $52.48 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618135
Principal investigator 1 Alkermes, Inc. $113.34 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622207
Principal investigator 1 Alkermes, Inc. $56.85 06/06/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624652
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738363
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $200.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738367
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $234.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738371
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.60 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738373
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738383
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $111.80 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738385
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $81.90 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738387
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738397
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738409
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $84.50 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738411
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $94.90 06/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738413
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $280.00 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738361
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738365
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738369
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $225.00 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738377
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,849.60 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738381
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,224.00 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738389
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,849.60 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738395
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738399
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $163.80 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738401
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $600.00 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738405
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738407
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $266.50 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738415
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,224.00 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738417
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $266.50 05/09/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738419
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,828.99 05/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738391
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $673.40 05/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738403
Principal investigator 1 Alkermes, Inc. $1,196.53 05/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619497
Principal investigator 1 Alkermes, Inc. $1,045.00 04/21/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626964
Principal investigator 1 Alkermes, Inc. $77.10 04/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622461
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $328.25 04/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738375
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,108.80 04/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738379
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $800.80 04/02/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738393
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,060.02 03/03/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738353
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613735
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614376
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615857
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617387
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621244
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622719
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622743
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622962
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623212
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624106
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625684
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,773.70 02/03/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738315
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $182.65 02/03/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738329
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738289
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $94.90 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738293
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738297
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738299
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738301
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $266.50 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738303
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $127.40 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738305
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738307
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $266.50 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738309
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $111.80 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $94.90 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738313
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $111.80 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738317
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $84.50 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738321
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,849.60 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738323
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738325
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.60 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738327
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.60 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738331
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,224.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738333
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $163.80 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738335
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $840.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738337
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $234.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738339
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.60 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738341
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738345
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $225.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738347
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738349
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $234.00 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738351
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $84.50 01/22/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738355
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,757.00 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738291
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738295
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,107.50 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738319
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,346.00 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738343
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $967.20 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738357
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,773.70 01/17/2025 Non-covered Recipient Entity
Comprehensive Sleep Medicine Associates PA
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738359
Principal investigator 1 Alkermes, Inc. $610.00 01/03/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615829
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627120
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627196
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
COMPREHENSIVE SLEEP MEDICINE ASSOCIATES CSMA
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627266